{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:03:18Z","timestamp":1787068998719,"version":"build-2736575974"},"reference-count":29,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Rhinol\ufffdAllergy"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epistaxis is a very common ENT emergency with the idiopathic variety being the commonest type. Daflon\u00ae is a mixture of flavonoids with beneficial vascular effects that may help in the treatment of epistaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of Daflon\u00ae in the treatment of idiopathic epistaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is an open-label randomized clinical trial conducted on patients with idiopathic epistaxis comparing 1 group receiving Daflon\u00ae for 1 month and a second group receiving Daflon\u00ae for 3 months with a control group receiving nothing. The groups were evaluated regarding the number of visits to an emergency room and the number of patients needing cautery as indicators for the control of epistaxis. Also, the severity of epistaxis was assessed using epistaxis severity score (ESS) before and after treatment. We followed the patients for 1 year to determine the long-term effect of both drug protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 450 patients distributed equally among the 3 study groups. The administration of Daflon\u00ae whether for 1 month or 3 months resulted in a significant improvement in our indicators for control of epistaxis including the number of patients visiting an emergency room and those needing cauterization after the failure of light nasal packing when compared with control group. Also, the severity of epistaxis as defined by the ESS was significantly less at the end of each treatment period and at 1-year follow-up when compared with the pretreatment severity. However, the use of Daflon\u00ae for 3 months was associated with a significantly more epistaxis control at 1-year follow-up when compared with the 1-month administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Daflon\u00ae is a very effective and safe method for controlling idiopathic epistaxis. However, the daily use of Daflon\u00ae for 3 months has a more significant long-term beneficial effect than 1 month of use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1945892418809237","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T11:03:18Z","timestamp":1541415798000},"page":"62-68","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Daflon\u00ae in the Treatment of Idiopathic Epistaxis"],"prefix":"10.1177","volume":"33","author":[{"given":"Tamer M.","family":"Attia","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, Faculty of Medicine, Menoufia University, Al Minufya, Egypt"},{"name":"Department of Otolaryngology, Head and Neck Surgery, Specialized Medical Care Hospital, Al Ain, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2004.025007"},{"key":"e_1_3_3_3_2","first-page":"91","article-title":"REKAS (recurrent epistaxis from Kiesselbach\u2019s area syndrome).","volume":"15","author":"Mladina R.","year":"1985","unstructured":"Mladina R. REKAS (recurrent epistaxis from Kiesselbach\u2019s area syndrome). Chir Maxillofac Plast. 1985; 15:91\u201395.","journal-title":"Chir Maxillofac Plast"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-5335-9_13"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666151111143616"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1947.00690020700011"},{"issue":"50","key":"e_1_3_3_7_2","first-page":"2661","article-title":"[Citrin in some cases of epistaxis]","volume":"36","author":"Albano V.","year":"1949","unstructured":"Albano V. [Citrin in some cases of epistaxis]. Prensa Med Argent. 1949; 36(50):2661.","journal-title":"Prensa Med Argent"},{"issue":"1","key":"e_1_3_3_8_2","first-page":"19","article-title":"Nocturnal leg cramps, easy bruisability and epistaxis in menopausal patients: treated with hesperidin and ascorbic acid.","volume":"31","author":"Horoschak A.","year":"1959","unstructured":"Horoschak A. Nocturnal leg cramps, easy bruisability and epistaxis in menopausal patients: treated with hesperidin and ascorbic acid. Del Med J. 1959; 31(1):19\u201322.","journal-title":"Del Med J"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363010-00005"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20818"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ar.1091680102"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2009.06.034"},{"key":"e_1_3_3_13_2","first-page":"333","article-title":"A re-evaluation of etiologic factors of hemorrhoidal disease.","volume":"24","author":"McGivney J.","year":"1967","unstructured":"McGivney J. A re-evaluation of etiologic factors of hemorrhoidal disease. Arizona Med. 1967; 24:333\u2013336.","journal-title":"Arizona Med"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1974.01360030110031"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570161052773870"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/713774007"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2000.102724"},{"issue":"1","key":"e_1_3_3_18_2","first-page":"69","article-title":"A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility","volume":"12","author":"Galley P","year":"1993","unstructured":"Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol. 1993; 12(1):69\u201372.","journal-title":"Int Angiol"},{"issue":"6","key":"e_1_3_3_19_2","first-page":"574","article-title":"Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.","volume":"45","author":"Godeberge P.","year":"1994","unstructured":"Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology. 1994; 45(6 Pt 2):574\u2013578.","journal-title":"Angiology"},{"issue":"6","key":"e_1_3_3_20_2","first-page":"566","article-title":"Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.","volume":"45","author":"Cospite M.","year":"1994","unstructured":"Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology. 1994; 45(6 Pt 2):566\u2013573.","journal-title":"Angiology"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800820809"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02237246"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2000.01448.x"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1479-666X(04)80032-5"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X104803"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2174\/157016109788340758"},{"issue":"5","key":"e_1_3_3_27_2","first-page":"428","article-title":"Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial.","volume":"34","author":"Rabe E","year":"2015","unstructured":"Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015; 34(5):428\u2013436.","journal-title":"Int Angiol"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-9590.18.03975-5"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/000331979404500614"},{"key":"e_1_3_3_30_2","first-page":"CD003974","article-title":"Placebo treatment versus no treatment","volume":"1","author":"Hr\u00f3bjartsson A","year":"2003","unstructured":"Hr\u00f3bjartsson A, G\u00f8tzsche PC. Placebo treatment versus no treatment. Cochrane Database Syst Rev. 2003; 1:CD003974.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["American Journal of Rhinology &amp; Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1945892418809237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1945892418809237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1945892418809237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:36:01Z","timestamp":1777368961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1945892418809237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1177\/1945892418809237"],"URL":"https:\/\/doi.org\/10.1177\/1945892418809237","relation":{},"ISSN":["1945-8924","1945-8932"],"issn-type":[{"value":"1945-8924","type":"print"},{"value":"1945-8932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]}}}